Company Overview - NanoViricides, Inc. is a clinical stage company focused on developing broad-spectrum antivirals using host-mimetic nanomedicine technology that viruses cannot escape [2][4] - The company has developed NV-387, a novel antiviral drug that has completed Phase I human clinical trials and is preparing for a Phase II trial for treating MPox in Africa [4] - Additional clinical trials for NV-387 are planned for RSV, Influenza, COVID, and other respiratory infections, with expectations for efficacy against Measles virus as well [4] - The company also developed NV-HHV-1 for herpesvirus infections and NV-HIV-1 for HIV/AIDS treatment [4] - The overall market size for NV-387, NV-HHV-1, and NV-HIV-1 is estimated to be between $20 to $30 billion [4] Event Participation - NanoViricides will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City [2] - Anil R. Diwan, President & Executive Chairman, will host one-on-one meetings during the conference from 9:00 A.M. to 3:00 P.M. (ET) [3]